Compare Stocks: TLSA, VECT, CTMX, and SGMT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.47 -3.1%	$3.16	$2.43 ▼ $8.21	$555.64M	2.21	4.09 million shs	4.50 million shs
SGMT Sagimet Biosciences	$8.92 +0.5%	$9.95	$4.50 ▼ $11.45	$551.97M	3.46	1.43 million shs	1.23 million shs
TLSA Tiziana Life Sciences	$1.13 +2.7%	$1.02	$0.76 ▼ $2.30	$139.99M	0.45	669,938 shs	448,029 shs
VECT VectivBio	$16.85	$16.85	$4.25 ▼ $16.98	N/A	N/A	N/A	N/A

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	-3.14%	-6.08%	-32.33%	-34.31%	-26.71%
SGMT Sagimet Biosciences	+0.45%	-4.80%	-16.71%	+21.03%	+22.02%
TLSA Tiziana Life Sciences	+2.73%	-0.88%	+14.18%	-8.13%	-50.66%
VECT VectivBio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.47 -3.1%	$3.16	$2.43 ▼ $8.21	$555.64M	2.21	4.09 million shs	4.50 million shs
SGMT Sagimet Biosciences	$8.92 +0.5%	$9.95	$4.50 ▼ $11.45	$551.97M	3.46	1.43 million shs	1.23 million shs
TLSA Tiziana Life Sciences	$1.13 +2.7%	$1.02	$0.76 ▼ $2.30	$139.99M	0.45	669,938 shs	448,029 shs
VECT VectivBio	$16.85	$16.85	$4.25 ▼ $16.98	N/A	N/A	N/A	N/A

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	-3.14%	-6.08%	-32.33%	-34.31%	-26.71%
SGMT Sagimet Biosciences	+0.45%	-4.80%	-16.71%	+21.03%	+22.02%
TLSA Tiziana Life Sciences	+2.73%	-0.88%	+14.18%	-8.13%	-50.66%
VECT VectivBio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	2.83	Moderate Buy	$11.90	381.78% Upside
SGMT Sagimet Biosciences	2.58	Moderate Buy	$26.63	198.59% Upside
TLSA Tiziana Life Sciences	2.00	Hold	N/A	N/A
VECT VectivBio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TLSA, VECT, CTMX, and SGMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/5/2026	SGMT Sagimet Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$29.00
10/2/2026	SGMT Sagimet Biosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$25.00 ➝ $26.00
10/1/2026	SGMT Sagimet Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
10/1/2026	SGMT Sagimet Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
10/1/2026	SGMT Sagimet Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$33.00 ➝ $38.00
10/1/2026	SGMT Sagimet Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$29.00 ➝ $27.00
9/28/2026	SGMT Sagimet Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$29.00
9/24/2026	SGMT Sagimet Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell	$7.00
9/24/2026	SGMT Sagimet Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell	$7.00
9/22/2026	TLSA Tiziana Life Sciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/11/2026	CTMX CytomX Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$18.30M	29.41	N/A	N/A	$0.58 per share	4.26
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	$3.42 per share	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A
VECT VectivBio	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	11/5/2026 (Estimated)
SGMT Sagimet Biosciences	-$51.04M	-$1.28	N/A	N/A	N/A	N/A	-31.96%	-30.57%	11/12/2026 (Estimated)
TLSA Tiziana Life Sciences	-$18.43M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VECT VectivBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest TLSA, VECT, CTMX, and SGMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	CTMX CytomX Therapeutics	-$0.09	N/A	N/A	N/A	$10.43 million	N/A
8/11/2026	Q2 2026	SGMT Sagimet Biosciences	-$0.2510	-$0.26	-$0.0090	-$0.26	N/A	N/A
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A
VECT VectivBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	9.36	9.36
SGMT Sagimet Biosciences	N/A	45.03	45.02
TLSA Tiziana Life Sciences	N/A	N/A	N/A
VECT VectivBio	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
SGMT Sagimet Biosciences	87.86%
TLSA Tiziana Life Sciences	N/A
VECT VectivBio	N/A

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	3.80%
SGMT Sagimet Biosciences	11.50%
TLSA Tiziana Life Sciences	39.82%
VECT VectivBio	9.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	69	217.90 million	209.62 million	Optionable
SGMT Sagimet Biosciences	16	62.16 million	55.01 million	Optionable
TLSA Tiziana Life Sciences	10	127.26 million	76.58 million	Optionable
VECT VectivBio	30	N/A	N/A	No Data

TLSA, VECT, CTMX, and SGMT Headlines

Recent News About These Companies

Ironwood Pharma to acquire VectivBio for $1.15 bln

July 12, 2026 | nasdaq.com

VectivBio Announces Pricing of Initial Public Offering

June 16, 2026 | stockhouse.com

What Recent Medicare Pricing Terms Mean For The Ironwood Pharmaceuticals (IRWD) Investment Story

February 6, 2026 | finance.yahoo.com

Boston biotech settles lawsuit alleging misappropriation of GLP-2 analog intellectual property

December 23, 2025 | bizjournals.com

Biotech acquired by Ironwood faces allegations of misappropriating trade secrets

November 11, 2025 | bizjournals.com

Ironwood’s shares sink as FDA demands new trial for lead drug

April 15, 2025 | msn.com

A brain biotech launches with Roche’s spare parts

February 13, 2025 | biopharmadive.comB

Aravax Continues International Expansion with Appointment of Aled Williams as Chief Business Officer

January 21, 2025 | markets.businessinsider.com

CDR-Life Appoints Sarah Holland, PhD, as Chief Business Officer

December 5, 2024 | finance.yahoo.com

Recent advances in clinical practice: mastering the challenge—managing IBS symptoms in IBD

November 12, 2024 | gut.bmj.comG

Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight

September 23, 2024 | finance.yahoo.com

Etherio Group: 2024 CMI 25

September 21, 2024 | meetingsnet.comM

Compare with VectivBio Holding AG (VECT)

May 29, 2024 | msn.com

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

May 15, 2024 | finance.yahoo.com

Vicore Pharma Holding: Vicore Expands and Strengthens its Board of Directors

May 14, 2024 | finanznachrichten.de

Vicore Expands and Strengthens its Board of Directors

May 14, 2024 | finance.yahoo.com

IFLR Europe Awards 2024: shortlist revealed

February 8, 2024 | iflr.comI

Ironwood seals the deal on VectivBio merger

December 13, 2023 | msn.com

Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio

December 12, 2023 | finance.yahoo.com

Reverb Therapeutics Debuts Its Amplifier™ Platform for Redirecting Endogenous Cytokines

November 15, 2023 | tmcnet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA, VECT, CTMX, and SGMT Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$2.47 -0.08 (-3.14%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$2.48 +0.00 (+0.20%)

As of 10/8/2026 07:30 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Sagimet Biosciences NASDAQ:SGMT

$8.92 +0.04 (+0.45%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$8.91 -0.01 (-0.10%)

As of 10/8/2026 07:30 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Tiziana Life Sciences NASDAQ:TLSA

$1.13 +0.03 (+2.73%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$1.12 0.00 (-0.44%)

As of 10/8/2026 07:56 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

VectivBio NASDAQ:VECT

$16.85 0.00 (0.00%)

As of 10/7/2026

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TLSA, VECT, CTMX, and SGMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TLSA, VECT, CTMX, and SGMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TLSA, VECT, CTMX, and SGMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA, VECT, CTMX, and SGMT Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Sagimet Biosciences NASDAQ:SGMT

Tiziana Life Sciences NASDAQ:TLSA

VectivBio NASDAQ:VECT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TLSA, VECT, CTMX, and SGMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TLSA, VECT, CTMX, and SGMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TLSA, VECT, CTMX, and SGMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA, VECT, CTMX, and SGMT Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Sagimet Biosciences NASDAQ:SGMT

Tiziana Life Sciences NASDAQ:TLSA

VectivBio NASDAQ:VECT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools